Wyeth PremPro
Executive Summary
Low-dose formulation of PremPro hormone replacement therapy is "approvable" at FDA for treatment of vasomotor symptoms, AHP Chief Operating Officer Robert Essner says. "The idea that you can get the benefits of HRT now at a substantially lower dose, we think is the kind of momentum that we need to get the category back and the product back on a much more positive track." Approval of low-dose PremPro (conjugated estrogens/medroxyprogesterone acetate combo) is expected in the second half